357 related articles for article (PubMed ID: 23688841)
21. Characterization and validation of an in silico toxicology model to predict the mutagenic potential of drug impurities.
Valerio LG; Cross KP
Toxicol Appl Pharmacol; 2012 May; 260(3):209-21. PubMed ID: 22426359
[TBL] [Abstract][Full Text] [Related]
22. Detection of mutagenic impurities in carcinogens and noncarcinogens by high-pressure liquid chromatography and the Salmonella/microsome test.
Donahue EV; McCann J; Ames BN
Cancer Res; 1978 Feb; 38(2):431-8. PubMed ID: 340030
[TBL] [Abstract][Full Text] [Related]
23. Mutagens that are not carcinogens: faulty theory or faulty tests?
Zeiger E
Mutat Res; 2001 May; 492(1-2):29-38. PubMed ID: 11377241
[TBL] [Abstract][Full Text] [Related]
24. The cancer threshold of toxicological concern (TTC) in relation to foodstuffs and pharmaceuticals: A potentially useful concept compromised by a dubious derivation.
Snodin DJ
Hum Exp Toxicol; 2018 Aug; 37(8):789-802. PubMed ID: 29027486
[TBL] [Abstract][Full Text] [Related]
25. Guidelines and pharmacopoeial standards for pharmaceutical impurities: overview and critical assessment.
Snodin DJ; McCrossen SD
Regul Toxicol Pharmacol; 2012 Jul; 63(2):298-312. PubMed ID: 22507740
[TBL] [Abstract][Full Text] [Related]
26. Structure-based thresholds of toxicological concern--guidance for application to substances present at low levels in the diet.
Renwick AG
Toxicol Appl Pharmacol; 2005 Sep; 207(2 Suppl):585-91. PubMed ID: 16019047
[TBL] [Abstract][Full Text] [Related]
27. Assay of 855 test chemicals in ten tester strains using a new modification of the Ames test for bacterial mutagens.
McMahon RE; Cline JC; Thompson CZ
Cancer Res; 1979 Mar; 39(3):682-93. PubMed ID: 371791
[TBL] [Abstract][Full Text] [Related]
28. Prediction of rodent carcinogenic potential of naturally occurring chemicals in the human diet using high-throughput QSAR predictive modeling.
Valerio LG; Arvidson KB; Chanderbhan RF; Contrera JF
Toxicol Appl Pharmacol; 2007 Jul; 222(1):1-16. PubMed ID: 17482223
[TBL] [Abstract][Full Text] [Related]
29. Identification of 'genotoxic' and 'non-genotoxic' alerts for cancer in mice: the carcinogenic potency database.
Cunningham AR; Rosenkranz HS; Zhang YP; Klopman G
Mutat Res; 1998 Feb; 398(1-2):1-17. PubMed ID: 9626960
[TBL] [Abstract][Full Text] [Related]
30. A compilation of safety impact information for extractables associated with materials used in pharmaceutical packaging, delivery, administration, and manufacturing systems.
Jenke D; Carlson T
PDA J Pharm Sci Technol; 2014; 68(5):407-55. PubMed ID: 25336416
[TBL] [Abstract][Full Text] [Related]
31. Mechanistic QSAR of aromatic amines: new models for discriminating between homocyclic mutagens and nonmutagens, and validation of models for carcinogens.
Benigni R; Bossa C; Netzeva T; Rodomonte A; Tsakovska I
Environ Mol Mutagen; 2007 Dec; 48(9):754-71. PubMed ID: 18008355
[TBL] [Abstract][Full Text] [Related]
32. Carcinogenicity of the aromatic amines: from structure-activity relationships to mechanisms of action and risk assessment.
Benigni R; Passerini L
Mutat Res; 2002 Jul; 511(3):191-206. PubMed ID: 12088717
[TBL] [Abstract][Full Text] [Related]
33. A consortium-driven framework to guide the implementation of ICH M7 Option 4 control strategies.
Barber C; Antonucci V; Baumann JC; Brown R; Covey-Crump E; Elder D; Elliott E; Fennell JW; Gallou F; Ide ND; Jordine G; Kallemeyn JM; Lauwers D; Looker AR; Lovelle LE; McLaughlin M; Molzahn R; Ott M; Schils D; Oestrich RS; Stevenson N; Talavera P; Teasdale A; Urquhart MW; Varie DL; Welch D
Regul Toxicol Pharmacol; 2017 Nov; 90():22-28. PubMed ID: 28822875
[TBL] [Abstract][Full Text] [Related]
34. Structure-activity models of chemical carcinogens: state of the art, and new directions.
Benigni R; Bossa C
Ann Ist Super Sanita; 2006; 42(2):118-26. PubMed ID: 17033131
[TBL] [Abstract][Full Text] [Related]
35. Setting health-based residue limits for contaminants in pharmaceuticals and medical devices.
Conine DL; Naumann BD; Hecker LH
Qual Assur; 1992 Jun; 1(3):171-80. PubMed ID: 1344672
[TBL] [Abstract][Full Text] [Related]
36. Identification, control strategies, and analytical approaches for the determination of potential genotoxic impurities in pharmaceuticals: a comprehensive review.
Reddy AV; Jaafar J; Umar K; Majid ZA; Aris AB; Talib J; Madhavi G
J Sep Sci; 2015 Mar; 38(5):764-79. PubMed ID: 25556762
[TBL] [Abstract][Full Text] [Related]
37. Structure-based thresholds of toxicological concern (TTC): guidance for application to substances present at low levels in the diet.
Kroes R; Renwick AG; Cheeseman M; Kleiner J; Mangelsdorf I; Piersma A; Schilter B; Schlatter J; van Schothorst F; Vos JG; Würtzen G;
Food Chem Toxicol; 2004 Jan; 42(1):65-83. PubMed ID: 14630131
[TBL] [Abstract][Full Text] [Related]
38. Carcinogenicity of mutagens: predictive capability of the Salmonella mutagenesis assay for rodent carcinogenicity.
Zeiger E
Cancer Res; 1987 Mar; 47(5):1287-96. PubMed ID: 3815340
[TBL] [Abstract][Full Text] [Related]
39. Definitive relationships among chemical structure, carcinogenicity and mutagenicity for 301 chemicals tested by the U.S. NTP.
Ashby J; Tennant RW
Mutat Res; 1991 May; 257(3):229-306. PubMed ID: 1707500
[TBL] [Abstract][Full Text] [Related]
40. Mutagenicity assessment strategy for pharmaceutical intermediates to aid limit setting for occupational exposure.
Araya S; Lovsin-Barle E; Glowienke S
Regul Toxicol Pharmacol; 2015 Nov; 73(2):515-20. PubMed ID: 26454093
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
